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INTRODUCTION: Salivary duct carcinoma (SDC) is very rare, only 1–3% of all salivary gland tumors are
reported as SDC. SDCpredominantly occurs in elderlymales, SCD is characterized by an aggressive clinical
course of the disease with less than 60% ﬁve years survival from the day of initial diagnosis, lymph
nodemetastasis and facial nerve involvement is common, the current literature lacks protocol regarding
management of this entity and the advantage of adjuvant therapy has not been evaluated due to its rare
occurrence.
PRESENTATION OF CASE: We report patient with stage IV HER2/neu negative SDC successfully treated
with surgery followed by adjuvant radiotherapy, patient is followed up for 40 months without evidence
of recurrence or metastasis.
DISCUSSION: SDC is reported to be similar to mammary duct carcinoma in clinical and immunohistologic
typing, further it shows an association of expression of HER-2/neu and p53, with early local disease recur-
rence, distantmetastasis andsurvival, however; current casewasadequately followedupand reevaluated
after 26 months, MRI did not show evidence of recurrence.
CONCLUSION: SDC is a rare tumor and information on association of HER2/neu with survival is useful in
further research on this tumor.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Salivary gland cancers make up 5% of all head and neck cancers,
most common of them ismucoepidermoid carcinoma. Incidence of
salivary duct carcinoma (SDC) is very rare and reported 1–3% of all
salivary gland tumors [1,2].
SDC is uncommon and is characterized by noticeable similarity
to mammary duct carcinoma; it occurs predominantly in parotid
of elderly males, involvement of facial nerve is common, incidence
of cervical lymph nodal metastasis up to 73% [3], the aggressive
clinical course associated with high incidence of recurrence and
metastasis leads to poor survival in these patients. Similar tomam-
mary duct carcinoma, HER2/neu positivity is associated with poor
outcome in the patients with SDC, immunohistochemical typing
shows a very high proliferation rate of Ki-67 in this tumor [4].
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We report patient with HER2/neu (human epidermal growth
factor receptor 2) negative SDC, successfully treated with surgery
and adjuvant radiotherapy, patient is followed up for 40 months
without evidence of recurrence or metastasis.
2. Presentation of case
A 51 years old man presented with a hard swelling over right
parotid region, on clinical examination; the swelling was adher-
ent to overlying skin, a hard enlarged submandibular lymph nodes
were palpable, however; the facial nerve function was intact with-
out evidence of palsy of facial muscles. FNAC of themass suggested
adenocarcinoma, MRI image ﬁndings revealed well deﬁned hyper
intense nodule at inferior pole of the right parotid gland,measuring
1.7×1.4 centimeters. Multiple enlarged lymph nodes were seen at
level Ib, level II, level III, level IV and level V (Figs. 1 and 2, ). Patient
was evaluated for other co morbidities, posterior-anterior view of
X-ray chest and MRI abdomen showed normal ﬁndings.
Patientwasplanned for radicalparotidectomy, an incisionencir-
cling the parotid, around the adherent skin was planned, cervical
extension of same incisionwasmodiﬁed along neck crease and uti-
lized for neck dissection, intra operative ﬁndings showed tumor
extending up to the base of skull involving the internal jugular vein,
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Fig. 1. Coronal MRI view illustrating the extant of tumor.
facial nerve and adherent to mastoid process and styloid process,
right side neck dissection from level I to Vwas done sacriﬁcing right
facial nerve and part of internal jugular vein, three dimensional
adequate resection margin was achieved through drilling of mas-
toid and styloid processes, reconstructionwas donewith pectoralis
major myocutaneous ﬂap.
Gross examination of resection specimen showed skin cov-
ered mass measuring 15×12.5×8 cm with surface nodularity, cut
section showed salivary gland measuring 7.5×6.5×5.5 cm, a min-
imum 10mm over all margin around tumor was present.
The histological examination suggested Salivary Duct Carci-
noma with discerned lymphovascular emboli, nine of 45 dissected
Fig. 2. Axial MRI view illustrating the extant of tumor.
cervical lymphnodes revealedmetastasiswith no perinodal spread
or perineural spread. The largest nodemeasured 3.8×1.8×1.5 cm.
The diagnosis for SDCwas followedwithHER2/neu, the patientwas
tested negative in this case.
Post operativehealingwasuneventful; adjuvant radiotherapyof
60 gray was delivered through intensity modulated radiotherapy
(IMRT) starting on twenty seventh post operative day.
Patient had been followed for 40 months and did not show any
evidence of recurrence, MRI done after 26 months showed small
volume oval shaped node measuring 8mm in diameter at left level
III, rest of the scan showed normal ﬁndings, the FNAC for this node
was negative for malignancy. Fig. 3 illustrates the operative ﬁeld in
MRI post 26 months.
3. Discussion
SDC largely affects males (66%), with a mean age of presenta-
tion at 62.5 years, it occurs primarily in the parotid gland (78%;
submandibular gland, 12%; Minor salivary glands, 10%) [4]. The
diagnosis is usually established throughH&Estaining, however; the
immunohistochemical evaluation has a therapeutic importance.
The carcinogenesis of SDC disease is unknown, however; the
recent data suggests a critical role of oncogenic PIK3CA in early
stages of its development. The incidence of cervical lymph node
metastasis is greater in SDC to other parotid malignancies, approx-
imately two thirds of SDC patients present at T3 or T4 stage [4].
The prognosis of SDC is poor with less than 60% ﬁve year survival
[6,7], the factors considerable regarding prognosis are advanced
clinical presentation, resection margin positivity [8] and HER2/neu
positivity [4]. The current case reported at an advanced stage
with multiple cervical lymph nodal metastases, lymphovascular
emboli, extension to skull base and internal jugular vein, however,
absence of perineural spread, pre operative intact facial nerve func-
tion, adequate tumor free resection margins and negative status of
HER2/neu were favorable indicators.
SDC is reported to be similar to mammary duct carcinoma in
clinical and immunohistologic typing, Michael Jaehne et al. [4],
in their report of 50 cases with clinical and immunohistologic
typing of SDC showed an association of expression of HER-2/neu
and p53, with early local disease recurrence, distant metastasis
and survival (p value 0.05). They observed that 48% of patients
Fig. 3. Coronal MRI view after 26 months follow up.
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developed metastasis within an average period of 29 months post
surgery.
The reported patient was adequately followed up and reevalu-
ated after 26 months, FNAC of suspected node on MRI and rest of
the MRI did not show evidence of recurrence.
The association of HER2/neu positivity prompted research on
the possibility of delivering chemotherapeutic agents such as
trastuzumab, such therapy has been reported with better survival
and response in palliative cases in the review by Nabili et al. [9],
these authors have proposed routine examination of HER2/neu sta-
tus in all patients with SDCs [9].
AlthoughHER2/neupositivity of these tumors showed favorable
response to chemotherapeutic agents, ER down-regulation was
associated with adverse clinical features, this prompted attempts
to treat SDC through hormonal therapy, however; the results
were extremely variable, absence of uniform androgen or estro-
gen receptors in all the cases was the major factor determining
outcome [10], though morphologically SDC was similar to ductal
cell carcinoma of breast, there was signiﬁcant variation in recep-
tors distribution, a detailed review is presented by Simpson et al.
[10], proposing reclassiﬁcation of this entity.
Currently, the primary therapy for SDC is surgical resection
with adequate negative margins, aggressive approach of surgery
is stressed, patients often require radical parotidectomy even in
early stages, perineural spread is common and facial nerve is often
sacriﬁced to obtain oncologic clearance, regardless of location of
primary tumor ipsilateral neck dissection is mandatory, bilateral
neck dissection is indicated in patients with SDC of palate. Evalu-
ation of adjuvant radiotherapy was not possible in literature due
to paucity of cases, multi centric studies and reviews are required
to evaluate response of this tumor to various therapeutic options;
however; authors ﬁnd it justiﬁed to subject the patient in stage IV
disease to adjuvant radiotherapy as in this case.
4. Conclusion
SDC is a rare neoplasm with aggressive behavior, according to
literature prognosis is not good even in initial stages, aggressive
approach to surgery is justiﬁed and current case is successfully
followed up for a period of forty months without evidence of
recurrence. HER2/neu negativity might have some inﬂuence in this
regard; however; further research is needed to study SDC.
Written informed consent was obtained from the patient for
publication of this case report and accompanying images.
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